Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Sep 7. pii: S0302-2838(18)30624-9. doi: 10.1016/j.eururo.2018.08.029. [Epub ahead of print] No abstract available.

PMID:
30201510
2.

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.

Flippot R, Escudier B, Albiges L.

Drugs. 2018 Sep 5. doi: 10.1007/s40265-018-0970-y. [Epub ahead of print] Review.

PMID:
30187355
3.

Treating patients with renal cell carcinoma and bone metastases.

Guida A, Escudier B, Albiges L.

Expert Rev Anticancer Ther. 2018 Sep 5:1-9. doi: 10.1080/14737140.2018.1520097. [Epub ahead of print]

PMID:
30183421
4.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Aug 31. pii: S0302-2838(18)30593-1. doi: 10.1016/j.eururo.2018.08.008. [Epub ahead of print]

PMID:
30177291
5.

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic.

Patrikidou A, Maroun P, Patard JJ, Baumert H, Albiges L, Massard C, Loriot Y, Escudier B, Di Palma M, Arfi-Rouche J, Rocher L, Merabet Z, Bossi A, Fizazi K, Blanchard P.

Clin Transl Radiat Oncol. 2018 Jul 6;12:28-33. doi: 10.1016/j.ctro.2018.07.001. eCollection 2018 Aug.

6.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
7.

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.

Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, Theodore C, Albiges L, Stefan D, de Crevoisier R, Hennequin C, Lagrange JL, Grellard JM, Clarisse B, Licaj I, Habrand JL, Carrie C, Joly F.

Eur J Cancer. 2018 Jul;98:38-47. doi: 10.1016/j.ejca.2018.04.008. Epub 2018 Jun 1.

PMID:
29864737
8.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

PMID:
29860937
9.

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.

PMID:
29707790
10.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

PMID:
29617710
11.

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors.

Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B.

Clin Genitourin Cancer. 2018 Jun;16(3):e663-e667. doi: 10.1016/j.clgc.2017.12.014. Epub 2018 Jan 4.

PMID:
29428404
12.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
13.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

14.

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

PMID:
29223605
15.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
16.

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.

Urun Y, Leow JJ, Fay AP, Albiges L, Choueiri TK, Bellmunt J.

Crit Rev Oncol Hematol. 2017 Dec;120:120-126. doi: 10.1016/j.critrevonc.2017.10.012. Epub 2017 Nov 2. Review.

PMID:
29198325
17.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14.

PMID:
29149761
18.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
19.

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Guida A, Albiges L, Derosa L, Loriot Y, Massard C, Fizazi K, Escudier B.

Clin Genitourin Cancer. 2017 Dec;15(6):e1081-e1088. doi: 10.1016/j.clgc.2017.07.015. Epub 2017 Aug 12.

PMID:
28888866
20.

Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors.

O'Donnell E, Markt SC, Miller R, Bernard B, Albiges L, Beard C, Sweeney C.

Clin Genitourin Cancer. 2017 Aug 3. pii: S1558-7673(17)30234-3. doi: 10.1016/j.clgc.2017.07.024. [Epub ahead of print]

PMID:
28851592
21.

Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.

Miller RE, Markt SC, O'Donnell E, Bernard B, Albiges LK, Beard C, Sweeney CJ.

Eur Urol Focus. 2017 Dec;3(6):621-628. doi: 10.1016/j.euf.2016.10.005. Epub 2016 Oct 26.

PMID:
28753801
22.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
23.

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK.

J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23.

PMID:
28644771
24.

Testicular ultrasensitive Doppler preliminary experience: a feasibility study.

Rocher L, Gennisson JL, Ferlicot S, Criton A, Albiges L, Izard V, Bellin MF, Correas JM.

Acta Radiol. 2018 Mar;59(3):346-354. doi: 10.1177/0284185117713350. Epub 2017 Jun 1.

PMID:
28569117
25.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
26.

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.

Matias M, Le Teuff G, Albiges L, Guida A, Brard C, Bacciarelo G, Loriot Y, Massard C, Lassau N, Fizazi K, Escudier B.

Eur J Cancer. 2017 Jul;79:185-192. doi: 10.1016/j.ejca.2017.04.015. Epub 2017 May 13.

PMID:
28511146
27.

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.

Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albiges L, Baciarello G, Loriot Y, Fizazi K.

J Immunother Cancer. 2017 Apr 18;5:31. doi: 10.1186/s40425-017-0232-7. eCollection 2017.

28.

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A.

Angiogenesis. 2017 May;20(2):205-215. doi: 10.1007/s10456-017-9550-0. Epub 2017 Apr 11. Review.

PMID:
28401381
29.

Nivolumab in renal cell carcinoma: latest evidence and clinical potential.

Mazza C, Escudier B, Albiges L.

Ther Adv Med Oncol. 2017 Mar;9(3):171-181. doi: 10.1177/1758834016679942. Epub 2016 Dec 11. Review.

30.

Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.

Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR.

Clin Genet. 2017 Dec;92(6):606-615. doi: 10.1111/cge.13014. Epub 2017 May 2. Erratum in: Clin Genet. 2018 May;93(5):1118.

PMID:
28300276
31.

Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].

Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K.

Eur J Cancer. 2017 Apr;75:333. doi: 10.1016/j.ejca.2017.02.014. Epub 2017 Mar 7. No abstract available.

PMID:
28283351
32.

Renal cell carcinoma.

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V.

Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. Review.

33.

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.

Pradere P, Michot JM, Champiat S, Danlos FX, Marabelle A, Lambotte O, Albiges L, Le Pavec J.

Eur J Cancer. 2017 Apr;75:308-309. doi: 10.1016/j.ejca.2016.12.027. Epub 2017 Mar 1. No abstract available.

PMID:
28259013
34.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
35.

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O.

Ann Rheum Dis. 2018 Mar;77(3):468-470. doi: 10.1136/annrheumdis-2016-210820. Epub 2017 Feb 27. No abstract available.

PMID:
28242618
36.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

37.

A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.

Joly F, Eymard JC, Albiges L, Nguyen T, Guillot A, Rolland F, Spaeth D, Laguerre B, Lebret T, Kelkouli N, Slimane K, Ravaud A.

Support Care Cancer. 2017 Jul;25(7):2055-2062. doi: 10.1007/s00520-017-3594-y. Epub 2017 Feb 10.

PMID:
28188447
38.

Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position.

Albiges L, Choueiri TK.

Nat Rev Clin Oncol. 2017 Feb;14(2):82-84. doi: 10.1038/nrclinonc.2016.224. Epub 2017 Jan 10. No abstract available.

PMID:
28071677
39.

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J.

Ann Oncol. 2017 Jan 1;28(1):90-95. doi: 10.1093/annonc/mdw441.

40.

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Derosa L, Izzedine H, Albiges L, Escudier B.

Oncol Rev. 2016 Nov 24;10(2):298. eCollection 2016 Oct 10. Review.

41.

Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Staehler M, Volpe A, Powles T.

Eur Urol. 2017 May;71(5):719-722. doi: 10.1016/j.eururo.2016.11.034. Epub 2016 Dec 13.

PMID:
27986369
42.

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Review.

PMID:
27939075
43.

Burned-Out Testis Tumors in Asymptomatic Infertile Men: Multiparametric Sonography and MRI Findings.

Rocher L, Glas L, Bellin MF, Ferlicot S, Izard V, Benoit G, Albiges L, Fizazi K, Correas JM.

J Ultrasound Med. 2017 Apr;36(4):821-831. doi: 10.7863/ultra.15.08037. Epub 2016 Dec 3.

PMID:
27914180
44.

[CCAFU french national guidelines 2016-2018 on renal cancer].

Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Corréas JM, Gimel P, Long JA, Nouhaud FX, Ouzaïd I, Paparel P, Rioux-Leclercq N, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S27-S51. doi: 10.1016/S1166-7087(16)30702-3. French.

PMID:
27846932
45.

Cabozantinib for the treatment of renal cell carcinoma.

Escudier B, Lougheed JC, Albiges L.

Expert Opin Pharmacother. 2016 Dec;17(18):2499-2504. Epub 2016 Nov 22. Review.

PMID:
27835047
46.

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K.

Eur J Cancer. 2016 Dec;69:151-157. doi: 10.1016/j.ejca.2016.10.003. Epub 2016 Nov 4. Erratum in: Eur J Cancer. 2017 Apr;75:333.

PMID:
27821318
47.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.

Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.

48.

Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.

Bigot P, Bernhard JC, Flamand V, Gill I, Verhoest G, Beauval JB, Nouhaud FX, Suer E, Ploussard G, Hetet JF, Rigaud J, Baco E, Larré S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NS, Reix B, Matsugasumi T, Bakri AE, Albiges L, Soulié M, Patard JJ, Méjean A, Bensalah K; members of the Kidney Cancer group of the CCAFU.

Urol Oncol. 2017 Jan;35(1):35.e15-35.e19. doi: 10.1016/j.urolonc.2016.08.012. Epub 2016 Sep 28.

PMID:
27692834
49.

Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.

Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, Nathan P, Negrier S, Weiss C, Porta C, Grünwald V, Albiges L.

Eur J Cancer. 2016 Dec;69:226-235. doi: 10.1016/j.ejca.2016.08.004. Epub 2016 Sep 24.

PMID:
27680407
50.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.

Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Review.

Supplemental Content

Loading ...
Support Center